Literature DB >> 17382247

Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor.

David A Hess1, Jesper Bonde, Timothy P Craft, Timothy C Craft, Louisa Wirthlin, Sarah Hohm, Ryan Lahey, Laura M Todt, John F Dipersio, Steven M Devine, Jan A Nolta.   

Abstract

AMD3100 inhibits the interaction between SDF-1 and CXCR4, and rapidly mobilizes hematopoietic progenitors for clinical transplantation. However, the repopulating function of human cells mobilized with AMD3100 has not been characterized in comparison to cells mobilized with granulocyte-colony stimulating factor (G-CSF) in the same donor. Therefore, healthy donors were leukapheresed 4 hours after injection with AMD3100; after 10 days of drug clearance the same donor was mobilized with G-CSF, allowing a paired comparison of repopulation by mobilized cells. Transplantation of mononuclear cells (MNC) or purified CD34(+) cells was compared at limiting dilution into NOD/SCID mice. Human AMD3100-mobilized MNC possessed enhanced repopulating frequency in comparison to G-CSF-mobilized MNC from paired donors, and purified CD34(+) progenitors were at least as efficient as the G-CSF mobilized cells. The frequencies of NOD/SCID repopulating cells (SRC) were 1 SRC in 8.7 x 10(6) AMD3100-mobilized MNC compared to 1 SRC in 29.0 x 10(6) G-CSF-mobilized MNC, and 1 SRC in 1.2 x 10(5) AMD3100-mobilized CD34(+) cells compared to 1 SRC in 1.8 x 10(5) G-CSF-mobilized CD34(+) cells. Hematopoietic differentiation of transplanted progenitors was similar after AMD3100 or G-CSF-mobilization. Thus, AMD3100 mobilized peripheral blood represents a rapidly obtained, highly repopulating source of hematopoietic progenitors for clinical transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17382247      PMCID: PMC1868544          DOI: 10.1016/j.bbmt.2006.12.445

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  46 in total

Review 1.  The bicyclam AMD3100 story.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2003-07       Impact factor: 84.694

2.  A newly discovered class of human hematopoietic cells with SCID-repopulating activity.

Authors:  M Bhatia; D Bonnet; B Murdoch; O I Gan; J E Dick
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

3.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

Authors:  A Peled; I Petit; O Kollet; M Magid; T Ponomaryov; T Byk; A Nagler; H Ben-Hur; A Many; L Shultz; O Lider; R Alon; D Zipori; T Lapidot
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

4.  Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells.

Authors:  Hal E Broxmeyer; Lisa Kohli; Chang H Kim; Younghee Lee; Charlie Mantel; Scott Cooper; Giao Hangoc; Montaser Shaheen; Xiaxin Li; D Wade Clapp
Journal:  J Leukoc Biol       Date:  2003-05       Impact factor: 4.962

5.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.

Authors:  W Conrad Liles; Hal E Broxmeyer; Elin Rodger; Brent Wood; Kai Hübel; Scott Cooper; Giao Hangoc; Gary J Bridger; Geoffrey W Henson; Gary Calandra; David C Dale
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

6.  Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor.

Authors:  David A Hess; Krysta D Levac; Francis N Karanu; Michael Rosu-Myles; Martin J White; Lisa Gallacher; Barbara Murdoch; Michael Keeney; Pamela Ottowski; Ronan Foley; Ian Chin-Yee; Mickie Bhatia
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

7.  The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1.

Authors:  R Möhle; F Bautz; S Rafii; M A Moore; W Brugger; L Kanz
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

8.  Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo.

Authors:  Hal E Broxmeyer; Scott Cooper; Lisa Kohli; Giao Hangoc; Younghee Lee; Charlie Mantel; D Wade Clapp; Chang H Kim
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

9.  Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization.

Authors:  Thalia Papayannopoulou
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

10.  Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.

Authors:  Steven M Devine; Neal Flomenberg; David H Vesole; Jane Liesveld; Daniel Weisdorf; Karin Badel; Gary Calandra; John F DiPersio
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more
  27 in total

1.  Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.

Authors:  Evangelia Yannaki; Thalia Papayannopoulou; Erica Jonlin; Fani Zervou; Garyfalia Karponi; Angeliki Xagorari; Pamela Becker; Nikoleta Psatha; Ioannis Batsis; Panayotis Kaloyannidis; Varvara Tahynopoulou; Varnavas Constantinou; Asimina Bouinta; Konstantia Kotta; Aglaia Athanassiadou; Achilles Anagnostopoulos; Athanasios Fassas; George Stamatoyannopoulos
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 2.  Getting blood from bone: an emerging understanding of the role that osteoblasts play in regulating hematopoietic stem cells within their niche.

Authors:  Yusuke Shiozawa; Russell S Taichman
Journal:  Exp Hematol       Date:  2012-05-26       Impact factor: 3.084

3.  Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.

Authors:  Ayelet Dar; Amir Schajnovitz; Kfir Lapid; Alexander Kalinkovich; Tomer Itkin; Aya Ludin; Wei-Ming Kao; Michela Battista; Melania Tesio; Orit Kollet; Neta Netzer Cohen; Raanan Margalit; Eike C Buss; Francoise Baleux; Shinya Oishi; Nobutaka Fujii; Andre Larochelle; Cynthia E Dunbar; Hal E Broxmeyer; Paul S Frenette; Tsvee Lapidot
Journal:  Leukemia       Date:  2011-04-15       Impact factor: 11.528

Review 4.  Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand.

Authors:  Louis M Pelus
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

5.  Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.

Authors:  Robert E Donahue; Ping Jin; Aylin C Bonifacino; Mark E Metzger; Jiaqiang Ren; Ena Wang; David F Stroncek
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

Review 6.  Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors:  M P Rettig; G Ansstas; J F DiPersio
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

Review 7.  Physiology and pharmacology of plerixafor.

Authors:  Simon P Fricker
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

8.  Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone.

Authors:  Maria Rosa Lidonnici; Annamaria Aprile; Marta Claudia Frittoli; Giacomo Mandelli; Ylenia Paleari; Antonello Spinelli; Bernhard Gentner; Matilde Zambelli; Cristina Parisi; Laura Bellio; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini; Fabio Ciceri; Sarah Marktel; Giuliana Ferrari
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941

Review 9.  The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span.

Authors:  Primož Rožman
Journal:  Geroscience       Date:  2018-06-14       Impact factor: 7.713

Review 10.  Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.

Authors:  Antona J Wagstaff
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.